Oliver Lagore Vanvalin Investment Group Purchases 4,945 Shares of Novo Nordisk A/S (NYSE:NVO)

Oliver Lagore Vanvalin Investment Group grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 69.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,091 shares of the company’s stock after buying an additional 4,945 shares during the quarter. Oliver Lagore Vanvalin Investment Group’s holdings in Novo Nordisk A/S were worth $1,251,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Pacific Center for Financial Services increased its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares in the last quarter. Copeland Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after purchasing an additional 141 shares in the last quarter. Bell Investment Advisors Inc increased its stake in shares of Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares in the last quarter. Citizens National Bank Trust Department increased its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock worth $27,000 after purchasing an additional 150 shares in the last quarter. Finally, Tyler Stone Wealth Management increased its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after purchasing an additional 146 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 1.5 %

Shares of NYSE:NVO traded down $1.85 during trading on Thursday, reaching $122.68. 2,016,226 shares of the company were exchanged, compared to its average volume of 4,869,867. The firm has a market capitalization of $550.53 billion, a PE ratio of 45.51, a P/E/G ratio of 2.06 and a beta of 0.41. The business’s fifty day simple moving average is $126.28 and its 200-day simple moving average is $110.42. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.05. The company had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.33 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were issued a dividend of $0.664 per share. This represents a yield of 0.9%. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

Analyst Upgrades and Downgrades

NVO has been the subject of several research reports. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday. UBS Group assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.